Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that the company has entered into an agreement with Novartis to acquire Anthos for up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor that originated at Novartis, being developed to prevent stroke and systemic embolism in patients with atrial fibrillation as well as to prevent the recurrence of blood clots in patients with cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210114240/en/
“Abelacimab has the potential to be an important treatment option for the millions of patients globally with atrial fibrillation at high risk of stroke, and we could not have more conviction in the potential of this asset,” said Bill Meury, Chief Executive Officer at Anthos. “With its deep roots in the cardiovascular space, Novartis is especially well positioned to advance abelacimab’s clinical development and bring this innovative product to healthcare providers and patients. I am deeply grateful to the Anthos and Blackstone Life Sciences teams, the clinical investigators, the patients in our studies, the advocacy community, and many others who have played a role in Anthos’ success over the past six years.”
“We are proud to have launched and helped grow Anthos by acquiring the rights to abelacimab, assembling a world class team, designing the clinical plan and financing its development,” said Dr. Nicholas Galakatos, Chairman of Anthos’ Board of Directors and Global Head of Blackstone Life Sciences. “We believe abelacimab has the potential to be a leader in the new class of Factor XI anticoagulants and are pleased to have Novartis as a committed partner to advance the development and commercialization of abelacimab as a potential treatment option for the millions of patients at risk of strokes. This transaction is an affirmation of Blackstone Life Sciences’ ownership investment strategy, where we seek to find innovative products and build companies around them to meet unmet patient needs.”
In AZALEA-TIMI 71, abelacimab compared with rivaroxaban (Xarelto) demonstrated a 62% reduction in major bleeding or clinically relevant non-major bleeding, a 67% reduction in major bleeding, and an 89% reduction in gastrointestinal bleeding. The overall clinical benefit of abelacimab prompted the Independent Data Monitoring Committee to discontinue the study early. Results from AZALEA-TIMI 71 were recently published in the New England Journal of Medicine on January 23, 2025.
Anthos is currently conducting a phase 3 clinical study in patients with atrial fibrillation with high risk for stroke or systemic embolism (LILAC-TIMI 76) as well as two phase 3 studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.
Blackstone Life Sciences’ investment in and commitment to Anthos demonstrate the power of combining its scale and deep operating expertise to build businesses that can help bring innovative products to market and substantially improve patient outcomes.
Transaction Details
Anthos shareholders will receive an upfront payment of $925 million upon closing of the transaction. In addition, Anthos shareholders are entitled to receive payments in the event certain regulatory and commercial milestones are achieved. Completion of the transaction is expected in the first half of 2025, pending the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and satisfaction of other customary closing conditions.
Advisors
Goldman Sachs & Co. LLC is acting as the lead financial advisor to Anthos. Morgan Stanley & Co. LLC is also serving as a financial advisor, and Goodwin Procter LLP is serving as legal advisor to Anthos.
About Anthos Therapeutics
Founded by Blackstone Life Sciences (BXLS) in 2019, Anthos Therapeutics is a transformative, clinical-stage biopharmaceutical company with the exclusive global rights from Novartis Pharma AG to develop, manufacture and commercialize abelacimab. BXLS is the majority investor in the company and is joined by other partners including Novo Holdings. For more information about Anthos, visit the Company’s website or follow us on X and LinkedIn.
About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $12 billion in assets under management.
About Abelacimab
Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease.
Abelacimab received a Fast Track Designation from the FDA in July 2022 for the treatment of thrombosis associated with cancer. In September 2022, abelacimab was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the proposed acquisition of Anthos by Novartis, the expected timetable for completing the transaction, future opportunities for the combined businesses, the expected benefits of Novartis’ acquisition of Anthos, the development and commercialization of Anthos Therapeutics’ product candidates and the potential benefits of abelacimab. All statements, other than statements of historical facts, contained in this press release, including statements regarding the company’s strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “become,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Actual results may differ materially because of numerous risks and uncertainties including with respect to (i) the possibility that various conditions to the consummation of the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the acquisition, (ii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iii) the risk that the milestones may not be achieved and resulting payments may not be realized, and (iv) unanticipated difficulties or expenditures relating to the proposed acquisition, including the response of business partners and competitors to the announcement of the proposed acquisition or difficulties in employee retention as a result of the announcement and pendency of the proposed acquisition. The actual financial impact of this transaction may differ from the expected financial impact described in this press release. In addition, the compounds described in this press release are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. No forward-looking statement can be guaranteed. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210114240/en/
Contacts
Blackstone
Paula Chirhart: Paula.Chirhart@blackstone.com
Anthos
Media contact: media@anthostherapeutics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Voyantis Raises $41M to Help Companies Transition to Efficient Growth, by Focusing on the RIGHT Customers at the RIGHT Time11.2.2025 16:33:00 EET | Press release
Voyantis, the AI-driven growth platform for customer acquisition and lifecycle optimization, announced it raised $41M in funding, bringing its total funding to $60M. Voyantis has tripled its ARR two years in a row and the funding will fuel and expedite its rapid growth trajectory. The round was led by Intel Capital with participation from Square Peg, Target Global, Jibe, Redseed, Alicorn, 20Growth, Essential and ICON. Intel Capital Investment Director Lisa Cohen will also join Voyantis’ board of directors to further accelerate the company’s growth. Voyantis was founded on the premise that evolving global economy fundamentals were causing companies to shift away from growth-at-all-costs strategies towards efficient and fiscally responsible growth practices, with a focus on improving Unit Economics. With a bold mission to reimagine, transform and streamline the whole growth process, Voyantis empowers growth teams to identify, acquire, engage, and retain their most valuable customers. Voy
Andersen Global Expands Legal Capabilities in Argentina11.2.2025 16:30:00 EET | Press release
Andersen Global continues to build its legal platform Latin America presence through Collaboration Agreements with MBP Partners and Schmukler IP, two law firms based in Buenos Aires. MBP Partners, founded in 2016 by Ignacio Meggiolaro and Victoria Bengochea, is recognized by Chambers, The Legal 500, and IFLR 1000 as a leading legal provider in Latin America. The firm advises local and international clients across the compliance and corporate governance sector, specializing in corporate and M&A law, banking and capital markets, mining and natural resources, compliance and anti-corruption, tax law and foreign trade, fintech, anti-money laundering, energy and hydrocarbons, governance law, and infrastructure. Founded in 1947, Schmukler IP operates with an experienced team of industrial property and legal professionals. The firm offers comprehensive intellectual property services, including patents, trademarks, service marks, models and designs, copyright, software protection, and domain na
Uniswap Labs Debuts Highly Anticipated Unichain To The Public11.2.2025 16:03:00 EET | Press release
Uniswap Labs, the leader in decentralized finance (DeFi), debuts Unichain to the public, a blockchain designed to take speed, efficiency, and cross-chain liquidity to the next level. Users and developers have processed over 88 million test transactions and 12 million test smart contracts on Unichain’s testnet in just a few months in anticipation of the launch. There will be 80+ applications and infrastructure providers supporting or building on Unichain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210091545/en/ (Graphic: Business Wire) Layer 2 (L2) blockchains like Unichain are critical for driving blockchain adoption with crypto traders, digital assets creators and institutions alike. They help alleviate congestion on Ethereum, enabling faster transactions, lower fees, and a seamless experience across blockchains. For everyday crypto users, this means cheaper and faster trading, access to integrated stablecoins like U
Opengear Announces CM8100-10G-5G: Streamlined Network Management With 5G Connectivity and Scalable Out of Band Access11.2.2025 16:00:00 EET | Press release
Opengear, a Digi International company (NASDAQ, DGII, www.digi.com) and provider of secure and Smart Out of Band™ management solutions, is pleased to announce the expansion of its CM8100-10G Console Manager series with the introduction of integrated 5G cellular technology. This release delivers the trusted connectivity, security, and operational efficiency support that customers rely on Opengear for while providing a leading-edge solution for their networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211382420/en/ Opengear announces CM8100-10G-5G: Streamlined Network Management with 5G Connectivity and Scalable Out of Band Access (Photo: Opengear) AI, IoT, and cloud computing are transforming how businesses operate. These technologies require low latency, high bandwidth, and always-on connectivity, pushing IT organizations to rethink how they deploy, manage, and secure critical infrastructure. When used with Opengear’
Bynder Accelerates AI Innovation by Expanding Bynder Labs With a New Team of Experts11.2.2025 15:25:00 EET | Press release
Bynder, a global leader in AI-powered enterprise DAM, has appointed some of the world’s leading experts to drive product innovation in its AI incubator, Bynder Labs. The company has appointed Machine Learning Engineer Aris Kalgreadis, User Researcher Jules Reijnen, and Data Scientist Ali Gharbali to Bynder Labs, who will collaborate with Bynder’s AI experts, Murat Akyol, Omri Walton, Cliff Crosbie, Michiel Maandag and Chief Legal Officer Ann-Michele Verheyden. The combined team along with Bynder’s already extensive product and engineering specialists will continue to drive innovation – pioneering next-generation solutions while addressing complex privacy, governance, and compliance issues. Bynder Labs is the company’s innovation program focused on the ideation and development of AI-driven capabilities for DAM. It was first introduced last year at the company’s inaugural customer conference, Bynder Connect, where the team showcased numerous technologies under development while capturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom